Finanzen von Keros Therapeutics Inc (KROS)KROSKeros Therapeutics Inc

Evaluating the bottom line, Keros Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15480.65%, while the net margin is -14282.83%. These profitability ratios, combined with a Return on Equity (ROE) of -17.16%, provide a clear picture of how effectively KROS converts its operational activities into shareholder value.

In the context of the broader market, KROS competes directly with industry leaders such as CHRS and SIGA. With a market capitalization of $200.25M, it holds a significant position in the sector. When comparing efficiency, KROS's gross margin of 100.00% stands against CHRS's 70.35% and SIGA's 57.17%. Such benchmarking helps identify whether Keros Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Keros Therapeutics has shown volatility in its financial performance, with a gross margin consistently at 100% but significant net income losses, such as -23,708,000 in Q1 2026 and -28,710,000 in Q2 2026. The company's revenue has also fluctuated, with a notable drop to only 367,000 in Q1 2026, down from 211,246,000 in Q1 2025.